

On convergence of the optimization process in Radiotherapy treatment planning

I. Hoveijn

University of Groningen, Department of Mathematics
P.O. Box 800, 9700 AV Groningen, The Netherlands

29/nov/2008

Abstract

The Radiotherapy treatment planning optimization process based on a quasi-Newton algorithm with an object function containing dose-volume constraints is not guaranteed to converge when the dose value in the dose-volume constraint is a critical value of the dose distribution. This is caused by finite differentiability of the dose-volume histogram at such values. A closer look near such values reveals that convergence is most likely not at stake, but it might be slowed down.

1 Introduction

A recent development in Radiotherapy treatment planning is to use an optimization process to obtain a treatment plan. To do so one needs to formalize the clinical objectives in a so called object function whose optimum should correspond to an optimal treatment plan. Many current treatment planning systems rely on a quasi-Newton algorithm to perform the optimization. In order to guarantee that this process indeed converges to an optimum the object function should at least be twice continuously differentiable. This last property is the main subject of this study. As it turns out the object functions used in Radiotherapy do not always have this property so that convergence of the optimization process can not directly be guaranteed in those cases.

In section 2 we present some background for the use of optimization in Radiotherapy treatment planning. The object functions currently used are built from so called dose-volume and EUD constraints. By dose-volume constraints, the dose-volume histogram enters the object function. It is the finite differentiability of the former that causes the insufficient differentiability of the latter. In section 3 this relationship is explained in more detail. An example illustrates how finite differentiability of the object function influences the optimization process. The practical consequences thereof are the subject of section 4. Where section 3 is kept informal, section 5 provides formal statements and proofs of the differentiability results. This last section does not contain new arguments but serves as a support for the exposition.

2 Background for optimization in Radiotherapy

2.1 Optimization in Radiotherapy

In Radiotherapy treatment planning a careful choice of values for treatment parameters is necessary to obtain a dose distribution in the patient that meets criteria for eradicating a malignant tumour. At the same time it should meet criteria so that healthy tissues and organs are not critically damaged. Due to the fact that dose is deposited in every irradiated part of the patient, these criteria are conflicting in almost every clinical situation. Experienced planners are usually very good at intuitively balancing such conflicting goals, still there is a need for more objective and quantifiable methods to devise and evaluate treatment plans. This has led to the construction of object functions, depending on treatment parameters, which formalize the objectives of dose on tumours and healthy tissues, see [1, 8, 9]. By optimizing this

object function with respect to treatment parameters, one hopes to get an optimal treatment plan. Another, very different, reason to use optimization in treatment planning is the emergence of IMRT where the sheer number of treatment parameters simply precludes manual planning.

Even if we know that a function has a unique optimum, there is no simple recipe to find it. Therefore we have to resort to numerical, iterative methods to solve optimization problems, which, given a starting point, generate a sequence converging to an optimum. The latter can be guaranteed only if certain conditions on the object function are met. It seems, however, that if these conditions are considered at all, it is taken for granted that they are fulfilled.

Many treatment planning systems use a quasi-Newton method, like the LBFGS algorithm, to find an optimum of the object function, see for example [2] or [7] as a general reference. One of the conditions guaranteeing that this algorithm yields a sequence locally converging to an optimum is that the object function is twice continuously differentiable. The object functions currently used in treatment planning systems are limited to so called *EUD constraints* and *dose-volume constraints*, or combinations of both, see for example [8], but also see section 2.2 remark 1. Our results show that the former do satisfy the differentiability condition. The latter however, do not, that is not for all values of the treatment parameters.

2.2 Object functions in Radiotherapy

The goal of Radiotherapy treatment planning is to devise a treatment plan achieving a high *tumour control probability* (TCP) combined with a low *normal tissue complication probability* (NTCP). A priori both TCP and NTCP are unrelated to treatment parameters. Even relating them to criteria on the dose distribution in the patient is a non-trivial task. To simplify matters one does not consider the 3-dimensional dose distribution, but a derived quantity namely the dose-volume histogram for each relevant region. The latter are tumours and healthy organs for which the dose-volume histogram tells which part of the volume receives at least a certain dose, see equation (1) below. Data from previously treated patients are used to relate TCP and NTCP to dose-volume histograms, see [3]. At this point further simplifications are necessary, because TCP and NTCP can only be related to certain points of dose-volume histograms or even only to averages. Generally for tumours this leads to dose-volume constraints, that is a minimum and a maximum dose for volumes v_{\min} and v_{\max} respectively, or in a more concise notation (d_{\min}, v_{\min}) and (d_{\max}, v_{\max}) . In case of healthy tissues the situation is much more complicated, in practice one uses a mixture of dose-volume constraints and EUD constraints, see [8].

Criteria for the dose distribution or the derived dose-volume histograms are related to treatment parameters, thus the treatment planning objectives can be expressed with an object function of these treatment parameters. Now the object function used in treatment planning is a weighted sum of 'local' object functions, one for each dose-volume constraint or EUD constraint. Let us consider a tumour with a minimum and a maximum dose-volume constraint. Furthermore V_σ is the dose-volume histogram of the tumour for a given dose distribution and treatment parameters σ , that is $V_\sigma(h)$ is the (relative) volume of the tumour, region R , receiving at least dose h

$$V_\sigma(h) = \text{vol}\{x \in R \mid f_\sigma(x) \geq h\}. \quad (1)$$

In this expression $\text{vol}(A)$ is the volume of the region A and f_σ is the dose distribution. One constructs what we will call *local object functions*. For example the local object function for a minimum dose-volume constraint for a specific volume is a function $F_{\min}(\sigma)$ which increases the more the actual relative volume at d_{\min} is below v_{\min} and decreases or even becomes zero if the actual relative volume at d_{\min} is above v_{\min} . Similarly a maximum dose object function $F_{\max}(\sigma)$ is constructed such that it increases when the relative volume at d_{\max} is above v_{\max} and decreases or becomes zero otherwise. Thus the object function for the tumour alone would be the weighted sum of two local object functions, usually of the following form

$$F(\sigma) = w_1 F_{\min}(\sigma) + w_2 F_{\max}(\sigma) = w_1 G(v_{\min} - V_\sigma(d_{\min})) + w_2 G(V_\sigma(d_{\max}) - v_{\max}), \quad (2)$$

where $w_1 > 0$ and $w_2 > 0$ are weights and

$$G(x) = \begin{cases} 0, & x < 0 \\ x^2, & x \geq 0, \end{cases} \quad (3)$$

Although the object function F is a function of the treatment parameters σ it does not depend on them directly, but only via the dose-volume histograms. The latter depend on the dose distribution which directly depends on the treatment parameters.

The EUD constraints are in a similar way expressed in the *equivalent uniform dose*. A quantity used to measure the biological effect of radiation especially for healthy tissues, see [6]. We denote the equivalent uniform dose by E_α , here it is a function of treatment parameters σ

$$E_\alpha(\sigma) = \left[\frac{1}{\text{vol}(R)} \int_R f_\sigma(x)^\alpha dx \right]^{1/\alpha}. \quad (4)$$

Remarks

1. The word *constraint* in this context is somewhat misleading because a dose-volume nor an EUD constraint is used as a constraint in the sense of constrained optimization. If they were, many if not most optimization problems in treatment planning would have no solution. It is a common clinical situation that a tumour is located adjacent to a critical organ. For several reasons the region, called PTV, on which the treatment dose is prescribed is larger than the tumour. See [5] for a systematic description of XTV's, where X = G, C, I or P. Therefore the critical organ is possibly partly located in the PTV. Suppose for example that one third of the volume of the critical organ is located inside the PTV. Furthermore suppose that the minimal dose-volume constraint on the PTV is 60 Gy (Gy is unit of dose) and the maximum average dose constraint on the organ is 20 Gy. Since the dose distribution varies continuously in space and its gradient is bounded, this constrained optimization problem will have no solution. Due to the anatomy a minimum dose of 60 Gy on the PTV implies an average dose well above 20 Gy on the organ and vice versa. A weighted sum of local object functions is a way to find a clinically acceptable compromise for this situation. To avoid the term *constraint* some authors use the term *soft constraint*, but in my opinion this term is superfluous because we already have the notion of object function. Nevertheless we adhere to the word *constraint*, in order to stay in line with the existing literature.
2. The equivalent uniform dose, as defined in equation (4), can be regarded as a generalized average, in fact for $\alpha = 1$ it is the standard average of the dose distribution over the region R . Formally it is identical to the L_p -norm of the dose distribution f_σ restricted to a region R of the patient. But p is called α and it has a biological interpretation. One associates a value of α to each tissue type, but there is no agreement yet in the literature about these values.
3. The dose-volume histogram refers to the graph of a function that is usually given the same name. This function, defined for each σ in equation (1), can be regarded as a volume function in the sense of [4]. Let us fix σ for the moment. The dose-volume histogram of a region R is a function $h \mapsto V_\sigma(h)$ whose value is the volume of R receiving at least dose h . In other words it gives the volume of a region enclosed by two level sets of the dose distribution f_σ , namely those $x \in R$ where $f_\sigma(x) = h$ and the $x \in R$ where $f_\sigma(x) = \max_R(f_\sigma)$ (this last level set will be a point).
4. Any quantity that influences the dose distribution may be considered as a *treatment parameter*. Usually treatment parameters are *beam intensities* and *beam angles*, that is parameters of the treatment unit.
5. The object function $F(\sigma)$ in equation (2) also depends on d_{\min} , d_{\max} , v_{\min} , v_{\max} , w_1 and w_2 . Such parameters might be called *planning parameters*. Here we will keep them fixed.

3 Differentiability of object functions in Radiotherapy

The numerical optimization process based on a quasi-Newton method converges locally to an optimum if the object function is at least twice continuously differentiable. In the sequel we will simply say differentiable. In current Radiotherapy practice the object function is a function of treatment parameters, but only indirectly via dose-volume constraints and or EUD constraints. Here we will consider their differentiability properties.

Let us start with object functions only containing EUD constraints. Then $F(\sigma)$ is a weighted sum of local object functions involving only

$$G(d_{\min} - E_{\alpha}(\sigma)) \text{ and } G(E_{\alpha}(\sigma) - d_{\max})$$

like in equations (2) and (3). In this case the object function F is differentiable. Here we have to assume that the dose distribution is differentiable.

However, when the object function contains dose-volume constraints it is not always differentiable. This is due to the finite differentiability of the dose-volume histogram at critical values of the dose distribution, even when the latter is differentiable. Since it is not immediately obvious how the differentiability of the dose-volume histogram as a function of dose affects the differentiability of the object function as a function of treatment parameters, we present the following explanation. Essentially, the treatment parameters enter the argument of the volume function because in the presence of parameters, the critical values are parameter dependent.

When treatment parameters vary, the dose distribution f_{σ} varies and in particular its critical values. Thus a critical value may pass through h . Suppose $x_{\sigma} = 0$ is a critical point for $\sigma = \sigma_0$ (a critical point can always be translated to 0). It can be shown, see section 5, that for values of σ near σ_0 and x near 0, f_{σ} can be transformed to a new function $\hat{f}_{\sigma}(x) = g(x) + f_{\sigma}(x_{\sigma})$. Where g is a σ independent local standard of f_{σ} with critical point at zero and critical value zero and $f_{\sigma}(x_{\sigma})$ is the critical value of \hat{f}_{σ} for σ near σ_0 .

Using the previous we will show in section 5 that $V_{\sigma}(h) = V_{\text{glob}}(\sigma, h) + V_{\text{loc}}(\sigma, h)$ can be split into a global and a local part. The global part depends differentiably on σ . Let us consider the local part in more detail. On a neighbourhood $\mathcal{O} \subset \mathbb{R}^3$ of 0 we have

$$\begin{aligned} V_{\text{loc}}(\sigma, h) &\propto \text{vol}\{x \in \mathcal{O} \mid \hat{f}_{\sigma}(x) \geq h\} \\ &= \text{vol}\{x \in \mathcal{O} \mid g(x) + f_{\sigma}(x_{\sigma}) \geq h\} \\ &= \text{vol}\{x \in \mathcal{O} \mid g(x) \geq h - f_{\sigma}(x_{\sigma})\} \\ &= V_g(h - f_{\sigma}(x_{\sigma})). \end{aligned}$$

The function $V_{\text{loc}}(\sigma, h)$ is proportional to the volume in the expression above and the proportionality factor is a differentiable function of σ . The last line in the formula above shows the volume function V_g for a region enclosed by level sets of g . According to [4] this function is not twice continuously differentiable at critical values of g . Thus $V_{\text{loc}}(\sigma, h)$ is not twice continuously differentiable at values of σ for which

$$h = f_{\sigma}(x_{\sigma}). \tag{5}$$

This, in turn, means that the object function F is not twice continuously differentiable at values of σ such that h is a critical value of f_{σ} .

Remarks

1. The function G in equation (3) is not differentiable at 0. This alone would already imply that the object function in (2) is not differentiable. However we will assume that we are in a situation like in remark 1 where we are looking for a compromise. This means we stay away from points where G is not differentiable.
2. Note that equation (5) defines a hyper surface Λ in parameter space \mathbb{R}^m . It will be $m-1$ -dimensional in most of its points, therefore we need to vary only one parameter to pass through Λ .
3. Throughout we assume that the dose distribution is a differentiable function. If it were less differentiable, the volume function would also be less differentiable for both critical and regular values.

3.1 Examples

The aim of this section is to provide two examples. One shows a differentiable object function, the other shows an object function that fails to be twice continuously differentiable at a certain value of the treatment parameters, here we take $\sigma = 0$. In the first case the Newton iteration converges to

an optimum, whereas in the second case the Newton iteration does not converge if one of the iterates becomes 0. To avoid lengthy calculations obscuring the points we wish to illustrate we will make several simplifications.




Figure 1: On the left the graph of $f_{\sigma_1}(x, 0, 0)$ and on the right the graph of $f_{\sigma_2}(x, 0, 0)$. d_+ , d_{\max} and d_c are explained in the text.

Let f_σ be a dose distribution on the region R . The object function consists of a single maximum dose-volume constraint (d_{\max}, v_{\max}) so $F(\sigma) = G(V_\sigma(d_{\max}), v_{\max})$. The difference between the two examples will be the dose distribution. Suppose for σ in a sufficiently large neighbourhood of σ_1 the dose distribution is a function with a single maximum and for a similar neighbourhood of σ_2 it is a function with two maxima for example:

$$f_{\sigma_1}(x, y, z) = \frac{1}{1 + x^2 + y^2 + z^2} \quad \text{and} \quad f_{\sigma_2}(x, y, z) = \frac{1}{1 + x^2 + y^2 + z^2} + \frac{1}{2 + (x - 4)^2 + y^2 + z^2}.$$

Here σ_1 and σ_2 are different parameter values. In figure 1 we draw the functions $f_{\sigma_1}(x, 0, 0)$ and $f_{\sigma_2}(x, 0, 0)$. For both dose distributions we call d_+ the value at the global maximum and d_c is the value of the other local maximum of f_{σ_2} . Both d_+ and d_c depend on the treatment parameters σ . Let us assume that always $d_c < d_{\max} < d_+$. Furthermore we assume that $V_\sigma(d_{\max}) < V_\sigma(d_c)$.

For σ near σ_1 the dose distribution has only one critical value namely d_+ so for $d < d_+$, $V_\sigma(d)$ is a differentiable function of σ which we call U . In the second case, where σ is near σ_2 , we will be particularly interested in $d = d_c$. For d near d_c but $d \neq d_c$, $V_\sigma(d)$ is again a differentiable function. At $d = d_c$, $V_\sigma(d) = U(\sigma) + V_g(d_c - d)$ can be split in a local and a global part, as in the previous section, where the global part is differentiable. We assume for simplicity that the global part is again U . The local part V_g is essentially a function of the following form

$$V_g(h) = \begin{cases} \alpha h^{\frac{3}{2}}, & h > 0 \\ 0, & h \leq 0, \end{cases}$$

where g is a local standard form of the dose distribution, α is a constant. Since the volume function V_g is not differentiable at 0, the object function (that we will construct shortly hereafter) is not differentiable at values of σ for which $d = d_c$. The latter defines a hyper surface Λ in parameter space of codimension one, which means that we need to vary only one parameter to cross Λ . Therefore we choose new parameters and the first one we take to be $d - d_c$. Only this parameter will be relevant for the example, we call it again σ , but now $\sigma \in \mathbb{R}$. Thus for the second dose distribution we finally have the following volume function:

$$V_\sigma(d) = \begin{cases} U(\sigma) + \alpha(-\sigma)^{\frac{3}{2}}, & \sigma < 0 \\ U(\sigma), & \sigma \geq 0. \end{cases} \quad (6)$$

Now we construct the object function. First we scale such that $v_{\max} = 1$. Then the object function for the first dose distribution is

$$F_1(\sigma) = (U(\sigma) - 1)^2.$$

The object function for the second dose distribution is given by almost the same formula, but U is replaced by the volume function in equation (6). The function U must satisfy several conditions so that it is consistent with the dose distributions we chose. First U must be differentiable and decreasing, furthermore $U(0) > 1$ since we assumed that $V_\sigma(d_{\max}) < V_\sigma(d_c)$. A possible choice is $U(\sigma) = \frac{15}{10 + \sigma}$.

In the first optimization problem the object function F_1 is differentiable so there are no difficulties in applying the Newton algorithm. However, in the second optimization problem the object function F_2 is

not twice continuously differentiable at $\sigma = 0$. Recall that the 1-dimensional Newton iteration for F is $\sigma_{n+1} = \phi(\sigma_n) = \sigma_n - \frac{F'(\sigma_n)}{F''(\sigma_n)}$. Fixed points σ_0 of ϕ correspond to extremal points of F if F'' is continuous and nonzero at σ_0 . Since the limit from the left of the second derivative of F_2 is unbounded, the Newton iteration has a fixed point at $\sigma = 0$ which is not related to an minimum or maximum of F_2 . But this 'spurious' fixed point is not stable for the Newton iteration ϕ . Only if $\sigma_n = 0$ the next iterates will also be zero. Therefore it does not lead to convergence to a non extremal point of F in general. Although it may slow down the convergence of the Newton iterates. For a graphical explanation see figure 2.




Figure 2: In the left figure, the graph of F_2 is indicated by a dashed line, F'_2 by a solid line and F''_2 by dotted line. The figure on the right shows a magnification of the graph of F'_2 near $\sigma = 0$. The dashed lines indicate how the Newton iterate σ_{n+1} is constructed from σ_n .

4 Conclusion

Our results show that the Radiotherapy treatment planning optimization process based on a quasi-Newton method locally converges to an optimum of the object function for most values of the treatment parameters. Only when the object function contains a dose-volume constraint (h, v) , convergence can not be guaranteed. The reason is that the object function is not sufficiently differentiable for values of the treatment parameters such that h is a critical value of the dose distribution f_σ . Although for all other values of σ , the object function is differentiable. The question remains whether this leads to practical consequences for optimization in treatment planning.

Let us take a closer look at the values of the treatment parameters for which the object function is not sufficiently differentiable. In parameter space these values of σ are determined by the equation $h = f_\sigma(x_\sigma)$, see section 3, expressing that h is a critical value of the dose distribution. Geometrically this equation defines a hyper surface Λ in parameter space. Roughly speaking Λ is $m - 1$ -dimensional so it has measure zero. This means that given a starting point for optimization, the Newton iteration scheme generates a sequence of points that will lie on Λ with probability zero. The points on Λ are spurious fixed points of the Newton iteration like in the example of the previous section. The reason is that we can generalize this example. First all types of extreme points of the dose distribution, namely minima, saddles and maxima lead to the same type of non-differentiability of the volume function. Second, also in higher dimensions the second derivative of the object function becomes unbounded at points of insufficient differentiability. Third, the spurious fixed points of the Newton iteration scheme are unstable. Our final conclusion is that in practice the convergence of the optimization process is most likely only slowed down near Λ .

5 Proof of differentiability statements

In order to make a statement about the differentiability of the object function, we need a few definitions. Let $\Sigma \subset \mathbb{R}^m$ be an open set of m treatment parameters. Let D be a domain in \mathbb{R}^3 representing the patient and let $R \subset D$ represent a tumour region or a healthy organ. For each $\sigma \in \Sigma$, the dose distribution is represented by a function $f_\sigma : D \rightarrow \mathbb{R}$ (here we do not consider f_σ as a distribution in the sense of generalized functions). A function is called *smooth* if it is infinitely many times continuously differentiable. We now assume that f_σ is a smooth function of position $x \in D$ and moreover smoothly dependent on the parameters $\sigma \in \Sigma$. *Critical points* of f_σ are points in D where the gradient of f_σ

vanishes, other points are called *regular points*. The value f_σ takes at a critical point is called a *critical value*. If the level set $\{x \in R \mid f_\sigma(x) = h\}$ contains no critical points, h is called a *regular value*. We now state our results on the differentiability of object functions containing EUD constraints and dose-volume constraints respectively.

Theorem 1 *Let the object function $F : \Sigma \rightarrow \mathbb{R}$ be given by $F(\sigma) = G(E_\alpha(\sigma), h)$, where $G : \mathbb{R} \times \mathbb{R} \rightarrow \mathbb{R}$ is a smooth function and $E_\alpha(\sigma)$ is the equivalent uniform dose. Then F is smooth with respect to σ .*

Theorem 2 *Let the object function $F : \Sigma \rightarrow \mathbb{R}$ be given by $F(\sigma) = G(V_\sigma(h), v)$, where $G : \mathbb{R} \times \mathbb{R} \rightarrow \mathbb{R}$ is a smooth function and V_σ is a volume function for dose distribution f_σ . Then F is smooth with respect to σ provided that h is not a critical value of f_σ . If h is a critical value of f_{σ_0} , then F is not twice continuously differentiable at $\sigma = \sigma_0$.*

The proof of theorem 1 is rather straightforward, but the proof of theorem 2 is more involved. Since in the setting of theorem 2 the differentiability of the object function F is completely determined by the volume function, the proof is about the latter only. The theorem contains two statements which we here state and prove separately. The proofs heavily rely on the results in [4], but due to the presence of parameters we have to make several adjustments. Let us start with some definitions.

Definitions

1. Let $f_\sigma : \mathbb{R}^n \rightarrow \mathbb{R}$ be a positive smooth function for all $\sigma \in \mathbb{R}^m$ and moreover f_σ depends smoothly on σ . For each $\sigma \in \Sigma$, f_σ vanishes at infinity in the following sense, for each $\varepsilon > 0$ there is a compact $K \subset \mathbb{R}^n$ such that for all $x \in \mathbb{R}^n \setminus K$, $f_\sigma(x) < \varepsilon$. We assume that critical points of f_σ are non-degenerate, that is if x is a critical point of f_σ then $\det(\text{Hess } f_\sigma(x)) \neq 0$.
2. Also $f : \mathbb{R}^n \times \mathbb{R}^m \rightarrow \mathbb{R}$ is a smooth function with non-degenerate critical points. Although we consider f and f_σ as different functions, their values are taken to be identical: $f(x, \sigma) = f_\sigma(x)$ for all $x \in \mathbb{R}^n$ and $\sigma \in \mathbb{R}^m$.
3. We denote the level sets of f_σ by $N_{h,\sigma} = \{x \in \mathbb{R}^n \mid f_\sigma(x) = h\}$.
4. The level sets of f are denoted by $\mathcal{N}_h = \{(x, \sigma) \in \mathbb{R}^n \times \mathbb{R}^m \mid f(x, \sigma) = h\}$.

Remark. Note that critical points of f are also critical points of f_σ , but the opposite is not necessarily true.

Proof of theorem 1. The function f_σ is a positive and smooth function, smoothly depending on parameters σ . Then $[f_\sigma]^\alpha$ for $\alpha > 0$ is also smooth in both variables and parameters. Now it immediately follows that $E_\alpha(\sigma)$ as defined in equation (4) is again a smooth function of σ . \square

The following two propositions essentially cover theorem 2.

Proposition 3 *Let f_σ and f be as defined above. Then $V_\sigma(h) = \text{vol}_n\{x \in \mathbb{R}^n \mid f_\sigma(x) \geq h\}$ depends smoothly on σ at $\sigma = \sigma_0$ if h is a regular value of f_{σ_0} .*

Proposition 4 *Let f_σ and $V_\sigma(h)$ be as in the previous proposition. Then $V_\sigma(h)$ is finitely differentiable with respect to σ at $\sigma = \sigma_0$ if h is a critical value of f_{σ_0} .*

Let us begin with the nice situation where h is a regular value of f_{σ_0} , so that $V_\sigma(h)$ smoothly depends on σ . In the proof of proposition 3 we use a property of the level sets $N_{h,\sigma}$ of f_σ .

Lemma 5 *Let f_σ and f be as defined above and furthermore h be a regular value of f_{σ_0} . Then an open neighbourhood Σ of σ_0 exists, such that $N_{h,\sigma}$ is diffeomorphic to N_{h,σ_0} for all $\sigma \in \Sigma$ and the diffeomorphism depends smoothly on σ .*

Proof of proposition 3. The volume $V_\sigma(h)$ is given by an integral over a region bounded by $N_{h,\sigma}$. Since, according to lemma 5, the latter depends smoothly on σ at $\sigma = \sigma_0$, the integral and thus $V_\sigma(h)$ depends smoothly on σ at $\sigma = \sigma_0$. \square

It remains to prove lemma 5.

Proof of lemma 5. Let $\{\sigma = \sigma_0\}$ be a shorthand for $\{(x, \sigma) \in \mathbb{R}^n \times \mathbb{R}^m \mid \sigma = \sigma_0\}$. Note that $N_{h, \sigma_0} = \{\sigma = \sigma_0\} \cap \mathcal{N}_h$. Since h is a regular value, N_{h, σ_0} contains no critical points of f_{σ_0} . Thus the intersection of $\{\sigma = \sigma_0\}$ and \mathcal{N}_h is transversal. Then a neighbourhood Σ of σ_0 exists such that for all $\sigma_1 \in \Sigma$, the intersection of $\{\sigma = \sigma_1\}$ and \mathcal{N}_h is transversal. Thus for all $\sigma_1 \in \Sigma$, N_{h, σ_1} is a regular level set, consequently there are no critical points of f in $\mathcal{N}_{h, \Sigma} = \{(x, \sigma) \in \mathbb{R}^n \times \mathbb{R}^m \mid x \in N_{h, \sigma}, \sigma \in \Sigma\}$. Suppose $\sigma_1 \in \Sigma$ and $\sigma_1 \neq \sigma_0$ then an index i exists such that $\sigma_{1,i} \neq \sigma_{0,i}$. Now the gradient flow of the height function σ_i on \mathcal{N}_h is a regular flow on $\mathcal{N}_{h, \Sigma}$ thus defining a diffeomorphism Φ from N_{h, σ_0} to N_{h, σ_1} . \square

Let us now turn to the case where h is a critical value of f_{σ_0} . Then there is at least one critical point x_{σ_0} in N_{h, σ_0} , but for the sake of simplicity we assume that x_{σ_0} is unique. In the proof of proposition 4 we will use a similar construction as in [4] without providing all details.

Proof of proposition 4. Let us assume that x_{σ_0} is the unique critical point of f_{σ_0} on the critical level set N_{h, σ_0} . Since by assumption x_{σ_0} is a non-degenerate critical point we can apply the implicit function theorem to conclude that an open neighbourhood Σ of σ_0 exists such that the map $\Sigma \rightarrow \mathbb{R}^n : \sigma \mapsto x_\sigma$ and x_σ is a critical point of f_σ is smooth. Now we define a new function $g_\sigma(x) = f_\sigma(x_\sigma + x)$, which is a smooth function of x and $\sigma \in \Sigma$. Moreover g_σ has a critical point at $x = 0$ with critical value $f_\sigma(x_\sigma)$. Then we have $V_\sigma(h) = \text{vol}_n\{x \in \mathbb{R}^n \mid g_\sigma(x) \geq h\}$. Following the construction in [4] we split the latter region in a part not containing the point 0 and a remaining small part including 0. The volume of the first part depends smoothly on σ using the same arguments proving proposition 3. Since $V_\sigma(h)$ is the sum of both volumes, the differentiability of $V_\sigma(h)$ is determined by that of the volume of the second part.

Let us consider this second part contained in a small neighbourhood \mathcal{O} of 0. We may assume that \mathcal{O} is small enough to put g_σ into the standard form of [4]. In order to keep notation simple we denote the standard form again by g_σ , but now we can write $g_\sigma(x) = g(x) + f_\sigma(x_\sigma)$. The actual standard form is $g(x) = \sum_{i=1}^p x_i^2 - \sum_{i=1}^q x_{p+i}^2$, with $p + q = n$. Note that g no longer depends on σ , it has a critical point at $x = 0$ and the critical value is 0. This form can be obtained by a smooth change of coordinates, even smoothly depending on σ . Here again we need the non-degeneracy of critical point of f_σ . In the following we use the results of [4]. As a function of k , the volume function $V_{\text{loc}}(k) = \text{vol}_n\{x \in \mathcal{O} \subset \mathbb{R}^n \mid g(x) \geq k\}$ is only finitely differentiable with respect to k at $k = 0$.

Now the volume of the second part is proportional to $V_{\text{loc}}(h - f_\sigma(x_\sigma)) = \text{vol}\{x \in \mathcal{O} \subset \mathbb{R}^n \mid g(x) \geq h - f_\sigma(x_\sigma)\}$. The proportionality factor is of no concern because it originates from smooth coordinate changes and depends smoothly on σ . Thus we obtain that the differentiability of $V_\sigma(h)$ with respect to σ is determined by that of $V_{\text{loc}}(h - f_\sigma(x_\sigma))$. The latter is only finitely differentiable with respect to σ at those values of σ where $h - f_\sigma(x_\sigma) = 0$. Or, put differently, where h is a critical value of f_σ . \square

Remarks

1. The statements and proofs in this section are valid for any dimension. Therefore we have not specialized them to the case $n = 3$. In this respect finitely differentiable means less than two times continuously differentiable.
2. The critical points of a parameter family of functions will generally be degenerate for certain parameter values. However we excluded this possibility because the volume function will be even less differentiable at a critical value when the critical point on the level set of this value is degenerate.

References

- [1] A. Brahme, Treatment Optimization using physical and radiobiological objective functions, in: "Radiation therapy physics", Alfred R. Smith (ed.) pp. 209-246, Springer Berlin, 1995.
- [2] R.H. Byrd, P. Lu, J. Nocedal, C. Zhu, A limited memory algorithm for bound constrained optimization, SIAM J. Sci. Comput. **16(5)** (1995) pp. 1190-1208.
- [3] A. Eisbruch, R.K. Ten Haken, H.M. Kim, L.H. Marsh, J.A. Ship, Dose, volume and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head

- and neck cancer, *International Journal of Radiation Oncology Biology and Physics* **45(3)** (1999) pp. 577-587.
- [4] I. Hoveijn, Differentiability of the volume of a region enclosed by level sets, *Journal of Mathematical Analysis and Applications*, **348** (2008) pp. 530-539.
 - [5] ICRU, Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50), ICRU Report 62, International commission on radiation units and measurements, 1999.
 - [6] A. Niemierko, Reporting and analyzing dose distributions: A concept of equivalent uniform dose, *Medical Physics* **24(1)** (1997) pp. 103-110.
 - [7] J. Stoer, R. Bulirsch, *Introduction to numerical analysis*, Springer 1983.
 - [8] C. Thielke, T. Bortfeld, A. Niemierko, From physical dose constraints to equivalent uniform dose constraints in inverse radiotherapy planning, *Med. Phys.* **30(9)** (2003) pp. 2332-2339.
 - [9] Q. Wu, R. Mohan, Algorithms and functionality of an intensity modulated radiotherapy optimization system, *Med. Phys.* **27(4)** (2000) pp. 701-711.